PROCEPT BioRobotics announced the launch of its HYDROS robotic system in the United Kingdom, Japan, and Korea, marking the first time the company will offer its next‑generation Aquablation platform outside the United States. The rollout begins in the UK on March 12, 2026, with subsequent entry into Japan and Korea later in the year.
The HYDROS system combines real‑time ultrasound imaging, AI‑driven treatment planning, and automated robotics to deliver a heat‑free, precision water‑jet ablation of prostate tissue. The platform’s AI‑enabled features, including FirstAssist AI, improve procedural efficiency and consistency, while the integrated imaging provides surgeons with real‑time guidance that reduces variability and enhances patient outcomes.
The international launch is a strategic lever for PROCEPT’s recurring‑revenue model. By expanding the installed base beyond the U.S., the company expects to increase procedural utilization and drive higher sales of consumable handpieces and service contracts. The move also positions PROCEPT to capture a larger share of the global BPH treatment market, reinforcing its competitive moat against non‑robotic alternatives.
PROCEPT’s Q4 2025 earnings miss—$76.1 million in revenue versus the $93.77 million expected—highlighted margin compression to 60.6% from 64% in the prior year. The company’s guidance for 2026 revenue was revised to $390 million–$410 million, reflecting concerns about near‑term demand and the need to invest in international expansion. The HYDROS launch is intended to offset these headwinds by opening new markets and generating additional recurring revenue streams.
Larry Wood, President and CEO, said, “Many men living with BPH remain on long‑term medication or delay surgery because they are concerned about potential trade‑offs between symptom relief and side effects. The HYDROS Robotic System expands international access to a clinically validated, next‑generation AI‑enabled robotic solution that delivers durable symptom relief while preserving quality of life. We are proud to bring this innovation to physicians and patients across the UK and to continue expanding our international footprint.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.